Last reviewed · How we verify
NCT05022823: DREAM
Exercise and Compression for Lymphedema
NA trial testing Compression sleeve, worn during exercise in Breast Cancer Related Lymphedema in 40 participants. Completed in 8 February 2024.
8 February 2024
Quick facts
| Lead sponsor | AHS Cancer Control Alberta |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 29 June 2022 |
| Primary completion | 8 February 2024 |
| Estimated completion | 8 February 2024 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Compression sleeve, worn during exercise
- Adjustable Compression (AC) garment, worn during exercise
- Compression sleeve, daytime wear
- Decongestive Progressive Resistance Exercise program
- Home exercise program
Conditions studied
- Breast Cancer Related Lymphedema — all drugs for Breast Cancer Related Lymphedema →
Sponsor
AHS Cancer Control Alberta — full company profile →
Who can join
18 and older, female only, with Breast Cancer Related Lymphedema. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to investigate the benefit of combining resistance exercise with use of a compression sleeve on arm lymphedema. In the study, participants will be taught a resistance exercise that follows the decongestive exercise sequence. This program is called "decongestive progressive resistance exercise" (DPRE). To evaluate the benefit from use of a compression garment on the arm. Some participants will wear their usual compression sleeve during exercise and others will use an adjustable compression wrap. The investigators hope to see if this type of combined program is helpful for women with lymphedema. The investigators also want to see if there are benefits from the addition of use of an adjustable compression wrap during exercise over use of a regularly prescribed compression sleeve.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Decongestive progressive resistance exercise with an adjustable compression wrap for breast cancer-related lymphoedema (DREAM): protocol for a randomised controlled trial.
Al Onazi MM, Campbell KL, Thompson RB, Ghosh S, et al · · 2022 · PMID 35379618 · DOI 10.1136/bmjopen-2021-053165
Verify or expand the search:
- PubMed search for NCT05022823
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer Related Lymphedema
Currently open trials in the same condition.
- NCT06697158 — Investigation of the Effects of Complex Decongestive Physiotherapy on Sleep Quality and Quality of Life in Women With Br · NA · recruiting
- NCT05682885 — The Effectiveness of Lymphatic Bypass Supermicrosurgery · NA · active not recruiting
- NCT04665882 — Nomogram to Predict Breast Cancer Related Lymphedema · NA · recruiting
Other AHS Cancer Control Alberta trials
Trials by the same sponsor.
- NCT05128734 — Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) · Phase 2 · not yet recruiting
- NCT06860542 — Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis · Phase 2 · recruiting
- NCT05345847 — Steroid Sparing in Immune Related Hepatitis (irH) · NA · recruiting
- NCT05407987 — Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery) · Phase 3 · recruiting
- NCT05421416 — Loratadine for the Prevention of G-CSF-related Bone Pain · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05022823 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AHS Cancer Control Alberta
- Last refreshed: 27 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05022823.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing